The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sergeeva N.S.

Russian University of Peoples' Friendship

Marshutina N.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Solokhina M.P.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Alentov I.I.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Kaprin A.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Clinical significance of CA 72-4 as a serological tumor-associated marker

Authors:

Sergeeva N.S., Marshutina N.V., Solokhina M.P., Alentov I.I., Kaprin A.D.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2019;8(2): 120‑125

DOI: 10.17116/onkolog20198021120

Read: 10522 times

Download PDF (RU)
Contact the author
Table of contents

CLINICAL SIGNIFICANCE OF CA 72-4 AS A SEROLOGICAL TUMOR-ASSOCIATED MARKER
CLINICAL SIGNIFICANCE OF CA 72-4 AS A SEROLOGICAL TUMOR-ASSOCIATED MARKER

To cite this article:

Sergeeva NS, Marshutina NV, Solokhina MP, Alentov II, Kaprin AD. Clinical significance of CA 72-4 as a serological tumor-associated marker. P.A. Herzen Journal of Oncology. 2019;8(2):120‑125. (In Russ.)
https://doi.org/10.17116/onkolog20198021120

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Study of serum cyto­kine concentration in primary patients with gastric cancer. P.A. Herzen Journal of Onco­logy. 2025;(2):25-29
Comparative analysis of longitudinal and transverse mini­laparotomy during colon cancer surgery. Piro­gov Russian Journal of Surgery. 2025;(4):71-78
The phenomenon of tumor budding in gastric cancer. Russian Journal of Archive of Pathology. 2025;(2):79-87
Total gastrectomy with preserving duodenal passage by double tract reco­nstruction in patients with gastric cancer. Piro­gov Russian Journal of Surgery. 2025;(6):35-43
Technical aspe­cts of lapa­roscopic formation of gastroduodenoanastomosis (Billroth-I) during distal rese­ction in patients with gastric cancer. Endo­scopic Surgery. 2025;(3):44-51
Diagnosis and treatment of ovarian cancer in pregnancy. Russian Bulletin of Obstetrician-Gynecologist. 2025;(3):27-33
Ergo­spirometry for preoperative risk asse­ssment in patients with colo­rectal cancer. Russian Journal of Anesthesiology and Reanimatology. 2025;(3):70-77
Microsatellite instability as a possible diagnostic marker of the gastric mucosa dysplasia. Russian Journal of Archive of Pathology. 2025;(3):5-16
Prognostic significance and comparison of methods for calculating tumor budding in gastric cancer. Russian Journal of Archive of Pathology. 2025;(3):17-25
Another sight at Gastric Cancer Mole­cular Classification: novel subtypes based on expression of CDX-2, E-cadherin, Epstein-Barr virus RNAs, MMR proteins. Russian Journal of Archive of Pathology. 2025;(3):49-61
Abstract:

The serological tumor-associated marker CA 72-4 is traditionally positioned as a marker for mucinous ovarian cancer and gastric cancer, being considered relatively highly tumor-specific. However, in clinical practice, some of the examinees without cancer processes were found to have an increase in the serum levels of the marker (by 2.0—2.5 times higher than the upper limit of the normal range). This served as a basis for revising the data available in the literature regarding this marker. The review presents the history of discovery of CA 72-4, its structure, cellular functions, and tissue and serum expression in different physiological states, in non-tumor pathological processes, and in benign and malignant tumors.

Keywords:

CA 72-4
ovarian cancer
gastric cancer
colorectal cancer

Authors:

Sergeeva N.S.

Russian University of Peoples' Friendship

Marshutina N.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Solokhina M.P.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Alentov I.I.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Kaprin A.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Close metadata

References:

  1. Colcher D, Hand PH, Nuti M, Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci. 1981;78(5):3199-3203. https://doi.org/10.1073/pnas.78.5.3199
  2. Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL, Colcher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res. 1986;46(2):850-857.
  3. Gero EJ, Colcher D, Ferroni P, Melsheimer R, Giani S, Schlom J, Kaplan P. CA 72-4 radioimmunoassay for the detection of the TAG-72 carcinoma-associated antigen in serum of patients. J Clin Lab Anal. 1989;3(6):360-369. https://doi.org/10.1002/jcla.1860030609
  4. Jin H, Wang X, Bing TB, Gao P, Lin JM, Liang SX. Microplate chemiluminescence enzyme immunoassay for the quantitative evaluation of carbohydrate antigen 72-4 in human serum. Chin Sci Bull. 2008;53(19):2958-2963. https://doi.org/10.1007/s11434-008-0428-9
  5. Sheer DG, Schlom J, Cooper HL. Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3. Cancer Res.1988;48(23):6811-6818.
  6. Katari RS, Fernsten PD, Schlom J. Characterization of the shed form of the human tumor-associated glycoprotein (TAG-72) from serous effusions of patients with different types of carcinomas. Cancer Res. 1990;50(16):4885-4890.
  7. Devine PL, McKenzie IF. Mucins: structure, function, and associations with malignancy. Bioessays. 1992;14(9):619-625. https://doi.org/10.1002/bies.950140909
  8. Laskarin G, Redzovic A, Vlastelic I, Haller H, Medancic SS, Solinas G, Rukavina D. Tumor-associated glycoprotein (TAG-72) is a natural ligand for the C-type lectin-like domain that induces anti-inflammatory orientation of early pregnancy decidual CD1a+ dendritic cells. J Reprod Immunol. 2011;88(1):12-23. https://doi.org/10.1016/j.jri.2010.10.001
  9. Kristofic I, Redzovic A, Laskarin G, Eminovic S, Haller H, Rukavina D. Role of tumor-associated glycoprotein-72 in the progression of endometrial adenocarcinoma: a proposed study. Med Hypotheses. 2015;84(5):413-416. https://doi.org/10.1016/j.mehy.2014.10.017
  10. Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res. 1986;46(6):3118-3124.
  11. Stanick D, Schuss A, Mishriki Y, Chao S, Thor A, Lundy J. Reactivity of the monoclonal antibody B72.3 with fetal antigen: correlation with expression of TAG-72 in human carcinomas. Cancer Investig. 1988;6(3):279-287. https://doi.org/10.3109/07357908809080650
  12. Guzman J, Izumi T, Nagai S, Costabel U. Immunocytochemical characterization of isolated human type II pneumocytes. Acta Cytol. 1994;38(4):539-542.
  13. Bartolazzi A, Mottolese M, Vocaturo A, Bigotti A, Vocaturo G, Atlante G, Prat M, Natali PG. Expression of CAR-3 and TAG-72 macromolecules in normal and transformed endometrium: potential diagnostic application in postmenopausal patients. Cancer Res. 1991;51(11):3001-3005.
  14. Ponnusamy MP, Venkatraman G, Singh AP, Chauhan SC, Johansson SL, Jain M, Smith L, Davis JS, Remmenga SW, Batra SK. Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis. Cancer Lett. 2007;251(2):247-257. https://doi.org/10.1016/j.canlet.2006.11.025
  15. Galietta A, Pizzi C, Pettinato G, Limite G, Sgambato A, Lamberti M, Muraro R, Formisano C, Pensabene M, Bianco AR, Mariani-Costantini R, Contegiacomo A. Differential TAG-72 epitope expression in breast cancer and lymph node metastases: a marker of a more aggressive phenotype. Oncol Rep. 2002;9(1):135-140. https://doi.org/10.3892/or.9.1.135
  16. Karan D, Johansson SL, Lin MF, Batra SK. Expression of tumor-associated glycoprotein-72 (TAG-72) antigen in human prostatic adenocarcinomas. Oncol Rep. 2001;8(5):1123-1126. https://doi.org/10.3892/or.8.5.1123
  17. Wang D, Zhang Y, Li X, Cui J, Wang S. A preliminary study on the expression of tumor-associated glycoprotein-72 in human gliomas. Med Oncol. 2012;29(3):2027-31. https://doi.org/10.1007/s12032-011-0027-5
  18. Szekanecz E, Szucs G, Szekanecz Z, Tarr T, Antal-Szalmás P, Szamosi S, Szántó J, Kiss E. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices. J Autoimmun. 2008;31(4):372-376. https://doi.org/10.1016/j.jaut.2008.08.008
  19. Arkhipkin AA, Lyang OV, Kochetov AG. The fetal proteins in prognosis of development of pneumonia in patients with ischemic stroke. Klinicheskaya laboratornaya diagnostika. 2014;59(12):13-16. (In Russ.)
  20. Lessey BA, Pindzola JA. Tumor-associated glycoprotein (TAG-72) in endometriotic implants. J Clin Endocrinol Metab. 1993;76(4):1075-1079. https://doi.org/10.1210/jcem.76.4.7682561
  21. Imai A, Horibe S, Takagi A, Takagi H, Tamaya T. Drastic elevation of serum CA125, CA72-4 and CA19-9 levels during menses in a patient with probable endometriosis. Eur J Obstet Gynecol Reprod Biol. 1998;78(1):79-81. https://doi.org/10.1016/s0301-2115(98)00003-7
  22. Shang X, Song C, Du X, Shao H, Xu D, Wang X. The serum levels of tumor marker CA19-9, CEA, CA72-4, and NSE in type 2 diabetes without malignancy and the relations to the metabolic control. Saudi Med J. 2017;38(2):204-208. https://doi.org/10.15537/smj.2017.2.15649
  23. Parisi L, Gini E, Baci D, Tremolati M, Fanuli M, Bassani B, Farronato G, Bruno A, Mortara L. Macrophage polarization in chronic inflammatory diseases: killers or builders? J Immunol Res. 2018;2018:8917804. https://doi.org/10.1155/2018/8917804
  24. Braga TT, Agudelo JSH, Camara NOS. Macrophages during the fibrotic process: M2 as friend and foe. Front Immunol. 2015;6:602. https://doi.org/10.3389/fimmu.2015.00602
  25. Schwartz AM, Silverberg SG, Fu YS, Nozawa S, Huang S, Tsukasaki K, Williams KR. Use of monoclonal antibodies MSN-1 and B72.3 in the prediction of the natural history of endometrial hyperplasia. Int J Gynecol Pathol. 1993;12(3):253-258. https://doi.org/10.1097/00004347-199307000-00009
  26. Scambia G, Benedetti Panici P, Perrone L, Sonsini C, Giannelli S, Gallo A, Natali PG, Mancuso S. Serum levels of tumour associated glycoprotein (TAG 72) in patients with gynaecological malignancies. Br J Cancer. 1990;62(1):147-151. https://doi.org/10.1038/bjc.1990.248
  27. Lenhard MS, Nehring S, Nagel D, Mayr D, Kirschenhofer A, Hertlein L, Friese K, Stieber P, Burges A. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors. Clin Chem Lab Med. 2009;47(5):537-542. https://doi.org/10.1515/CCLM.2009.134
  28. Buderath P, Kasimir-Bauer S, Aktas B, Rasch J, Kimmig R, Zeller T, Heubner M. Evaluation of a novel ELISA for the tumorassociated antigen CA 72-4 in patients with ovarian cancer. Future Sci OA. 2016;2(4):FSO145. https://doi.org/10.4155/fsoa-2016-0040
  29. Bayer B, Meier W, Steiber P, Albiez M, Eirmann W, Fateh-Moghadam A. Significance of CA72-4 in the diagnosis of ovarian cancer. In: Klapdor R, ed. Recent results in tumor therapy and diagnosis. Munich: Zuckschwedt-Verlag, 1990;111-112.
  30. Negishi Y, Iwabuchi H, Sakunaga H, Sakamoto M, Okabe K, Sato H, Asano G. Serum and tissue measurements of CA72-4 in ovarian patients. Gynecol Oncol. 1993;48:148-154. https://doi.org/10.1006/gyno.1993.1026
  31. Fayed ST, Ahmad SM, Kassim SK, Khalifa A. The value of CA 125 and CA72-4 in management of patients with epithelial ovarian cancer. Dis Markers. 1998;14(3):155-160. https://doi.org/10.1155/1998/738321
  32. Granato T, Midulla C, Longo F, Colaprisca B, Frati L, Anastasi E. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. Tumor Biol. 2012;33(5):1335-1339. https://doi.org/10.1007/s13277-012-0381-8
  33. Anastasi E, Manganaro L, Granato T, Panici PB, Frati L, Porpora MG. Is CA72-4 a useful biomarker in differential diagnosis between ovarian endometrioma and epithelial ovarian cancer? Dis Markers. 2013;35(5):331-335. https://doi.org/10.1155/2013/984641
  34. Vlahos NF, Economopoulos KP, Fotiou S. Endometriosis, in vitro fertilisation and the risk of gynaecological malignancies, including ovarian and breast cancer. Best Pract Res Clin Obstet Gynaecol. 2010;24(1):39-50. https://doi.org/10.1016/j.bpobgyn.2009.08.004
  35. Zygouris D, Leontara V, Makris GM, Chrelias C, Trakakis E, Christodoulaki Ch, Panagopoulos P. Endometrioid ovarian cancer arising from an endometriotic cyst in a young patient. Eur J Gynaecol Oncol. 2012;33(3):324-325.
  36. Terry KL, Schock H, Fortner RT, Hüsing A, Fichorova RN, Yamamoto HS, et al. A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort. Clin Cancer Res. 2016;22(18):4664-4675. https://doi.org/10.1158/1078-0432.CCR-16-0316
  37. Tocchi A, Costa G, Lepre L, Liotta G, Mazzoni G, Cianetti A, Vannini P. The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer. J Cancer Res Clin Oncol. 1998;124(8):450-455. https://doi.org/10.1007/s004320050198
  38. Sun Zh, Zhang N. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy. World J Surg Oncol. 2014;12:397. https://doi.org/10.1186/1477-7819-12-397
  39. Gaspar MJ, Arribas I, Coca MC, Diez-Alonso M. Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumor Biol. 2001;22(5):318-322. https://doi.org/10.1159/000050633
  40. Ucar E, Semerci E, Ustun H, Yetim T, Huzmeli C, Gullu M. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther. 2008;25(10):1075-1084. https://doi.org/10.1007/s12325-008-0100-4
  41. Ayude D, Rodríguez-Berrocal FJ, Ayude J, Blanco-Prieto S, Vázquez-Iglesias L, Vázquez-Cedeira M, Páez de la Cadena M. Preoperative serum CA 72.4 as prognostic factor of recurrence and death, especially at TNM stage II, for colorectal cancer. BMC Cancer. 2013;13:543. https://doi.org/10.1186/1471-2407-13-543
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.